Blackhawk Capital Partners LLC. Has $4.64 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Blackhawk Capital Partners LLC. grew its stake in Eli Lilly and Company (NYSE:LLY) by 14.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,012 shares of the company’s stock after purchasing an additional 756 shares during the quarter. Eli Lilly and Company makes up about 2.4% of Blackhawk Capital Partners LLC.’s holdings, making the stock its 8th largest position. Blackhawk Capital Partners LLC.’s holdings in Eli Lilly and Company were worth $4,641,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Wrapmanager Inc. boosted its position in shares of Eli Lilly and Company by 16.7% during the 4th quarter. Wrapmanager Inc. now owns 2,976 shares of the company’s stock valued at $2,297,000 after acquiring an additional 425 shares during the last quarter. Trifecta Capital Advisors LLC grew its stake in Eli Lilly and Company by 0.9% in the 4th quarter. Trifecta Capital Advisors LLC now owns 22,143 shares of the company’s stock worth $17,094,000 after buying an additional 196 shares in the last quarter. Pine Valley Investments Ltd Liability Co increased its holdings in shares of Eli Lilly and Company by 35.9% in the 4th quarter. Pine Valley Investments Ltd Liability Co now owns 10,532 shares of the company’s stock worth $8,131,000 after buying an additional 2,780 shares during the last quarter. Curio Wealth LLC bought a new position in Eli Lilly and Company in the fourth quarter valued at $312,000. Finally, Prasad Wealth Partners LLC purchased a new stake in Eli Lilly and Company during the fourth quarter valued at about $482,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.9 %

NYSE LLY opened at $881.83 on Tuesday. The stock has a market cap of $836.12 billion, a P/E ratio of 75.31, a price-to-earnings-growth ratio of 1.40 and a beta of 0.42. Eli Lilly and Company has a fifty-two week low of $711.40 and a fifty-two week high of $972.53. The stock has a 50 day simple moving average of $803.38 and a two-hundred day simple moving average of $847.92. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.68%. Eli Lilly and Company’s payout ratio is presently 51.24%.

Eli Lilly and Company announced that its Board of Directors has approved a stock buyback program on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

LLY has been the subject of a number of research reports. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Bank of America reaffirmed a “buy” rating and issued a $997.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research note on Friday, January 17th. Wolfe Research assumed coverage on shares of Eli Lilly and Company in a report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective for the company. Finally, Barclays decreased their target price on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,000.28.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.